Posttherapy [18F]FDOPA PET Findings in an Anaplastic Pleomorphic Xanthoastrocytoma With a BRAF V600E Mutation.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 42695161.
- Also identified by DOI 10.1097/RLU.0000000000006698.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anaplastic pleomorphic xanthoastrocytoma (APXA) is a rare pediatric high-grade glioma (pHGG). We report a 10-year-old boy with a left temporal APXA harboring a BRAF V600E mutation, who presented with generalized tonic-clonic seizures 3-4 times weekly, treated with combined BRAF and MEK inhibition. This case illustrates the utility of [18F]FDOPA PET in monitoring targeted therapy, providing metabolic information that preceded and complemented conventional imaging.